Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission

Talal Hilal, Vinay Prasad

Research output: Contribution to journalArticle

Abstract

The approval of blinatumomab based on achievement of undetectable minimal residual disease (MRD) in patients with B cell acute lymphoblastic leukaemia in complete remission is the first of its kind and raises important considerations. This drug might improve outcomes in this setting, although considerable evidence is needed to validate the performance of MRD as a surrogate end point and confirm the hypothesis.

Original languageEnglish (US)
JournalNature Reviews Clinical Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Lymphocytes
Biomarkers
Pharmaceutical Preparations
blinatumomab

ASJC Scopus subject areas

  • Oncology

Cite this

Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission. / Hilal, Talal; Prasad, Vinay.

In: Nature Reviews Clinical Oncology, 01.01.2018.

Research output: Contribution to journalArticle

@article{2737bf7361e64f49bfbdf6a8e5dc5cd3,
title = "Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission",
abstract = "The approval of blinatumomab based on achievement of undetectable minimal residual disease (MRD) in patients with B cell acute lymphoblastic leukaemia in complete remission is the first of its kind and raises important considerations. This drug might improve outcomes in this setting, although considerable evidence is needed to validate the performance of MRD as a surrogate end point and confirm the hypothesis.",
author = "Talal Hilal and Vinay Prasad",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41571-018-0087-y",
language = "English (US)",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission

AU - Hilal, Talal

AU - Prasad, Vinay

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The approval of blinatumomab based on achievement of undetectable minimal residual disease (MRD) in patients with B cell acute lymphoblastic leukaemia in complete remission is the first of its kind and raises important considerations. This drug might improve outcomes in this setting, although considerable evidence is needed to validate the performance of MRD as a surrogate end point and confirm the hypothesis.

AB - The approval of blinatumomab based on achievement of undetectable minimal residual disease (MRD) in patients with B cell acute lymphoblastic leukaemia in complete remission is the first of its kind and raises important considerations. This drug might improve outcomes in this setting, although considerable evidence is needed to validate the performance of MRD as a surrogate end point and confirm the hypothesis.

UR - http://www.scopus.com/inward/record.url?scp=85053435097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053435097&partnerID=8YFLogxK

U2 - 10.1038/s41571-018-0087-y

DO - 10.1038/s41571-018-0087-y

M3 - Article

C2 - 30181661

AN - SCOPUS:85053435097

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

ER -